Price
No data yet.
Social Signal Score
Analyst Ratings
21 analystsRevenue
$101.87M+721.27%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Michael E. Castagna
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 592
- Beta
- 1.09
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -4.62
Financials
Revenue
$101.87M+721.3%Net Income
$-23.22M-143.0%EBITDA
$-5.36MFree Cash Flow
$-37.76MEPS (diluted)
$-0.07-112.5%Shares Outstanding (diluted)
320.18M+231.8%Operating Expenses
$75.77MCash & Debt
$96.61MReturn of Capital
$0.00Revenue by Segment (annual)
$348.97MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $348.97M | $5.86M | $0.02 |
| 2024 | $285.50M | $27.59M | $0.10 |
| 2023 | $198.96M | $-11.94M | $-0.04 |
| 2022 | $99.77M | $-87.40M | $-0.44 |
| 2021 | $75.44M | $-80.93M | $-0.37 |
| 2020 | $65.14M | $-57.24M | $-0.26 |
| 2019 | $63.04M | $-51.90M | $-0.31 |
| 2018 | $27.86M | $-86.97M | $-0.60 |
| 2017 | $11.74M | $-117.33M | $-1.13 |
| 2016 | $174.76M | $125.66M | $1.37 |
| 2015 | $0.00 | $-368.44M | $-4.54 |
| 2014 | $0.00 | $-198.38M | $-2.57 |
| 2013 | $0.00 | $-191.49M | $-3.20 |
| 2012 | $35.0K | $-169.37M | $-4.68 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $0.03
- Implied price
- $0.51
- Return from $3.85
- -33.3% a year
To earn 15.0% a year on these assumptions you'd need to buy at $0.25 — -93.4% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 12 | 15 | 18 | 21 | 24 |
|---|---|---|---|---|---|
| -2.0% | -44.2% | -41.7% | -39.5% | -37.6% | -35.9% |
| 3.0% | -41.4% | -38.7% | -36.4% | -34.4% | -32.6% |
| 8.0% | -38.5% | -35.7% | -33.3% | -31.2% | -29.4% |
| 13.0% | -35.7% | -32.7% | -30.2% | -28.1% | -26.1% |
| 18.0% | -32.8% | -29.8% | -27.2% | -24.9% | -22.8% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
70+40.00%Social Signal Score
Mentions (15)
- Newszacks.com·3d ago·Positive
Should You Buy MannKind (MNKD) After Golden Cross? After reaching an important support level, MannKind Corporation (MNKD) could be a good stock pick from a technical perspective. MNKD recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.
View source ↗ - Newsmarketbeat.com·4d ago·Negative
MannKind Sees Q4 Profit and Record Revenue as Drug Launches Gain Traction MannKind NASDAQ: MNKD expects to be profitable and report record revenue in the fourth quarter as it builds on the launch of FUROSCIX ReadyFlow and the pediatric approval of inhaled insulin Afrezza, CEO Michael Castagna said at the Jefferies 2026 Global Healthcare Conference.
View source ↗ - Newsseekingalpha.com·5d ago·Positive
MannKind Corporation (MNKD) Presents at UBS Global Biopharma Conference 2026 Transcript MannKind Corporation (MNKD) Presents at UBS Global Biopharma Conference 2026 Transcript
View source ↗ - Newsseekingalpha.com·16d ago·Positive
MannKind Corporation (MNKD) Q3 2026 Earnings Call Transcript MannKind Corporation (MNKD) Q3 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·16d ago·Negative
MannKind Q3 Earnings Call Highlights MannKind NASDAQ: MNKD expects to return to profitability in the fourth quarter after reporting higher third-quarter revenue and a net loss, as the company's FUROSCIX ReadyFlow and pediatric Afrezza launches gain traction.
View source ↗ - Newszacks.com·17d ago·Negative
Compared to Estimates, MannKind (MNKD) Q3 Earnings: A Look at Key Metrics Although the revenue and EPS for MannKind (MNKD) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
View source ↗ - Newsmarketbeat.com·33d ago·Negative
MannKind Advances Inhaled IPF Drug to Global Phase 2, Eyes FUROSCIX Growth MannKind NASDAQ: MNKD Chief Executive Officer Mike Castagna said the company is advancing an inhaled version of nintedanib into a global Phase 2 study for idiopathic pulmonary fibrosis, or IPF, following early safety and tolerability results that did not show the gastrointestinal issues often associated with oral nintedanib.
View source ↗ - Newsbenzinga.com·34d ago·Positive
This MannKind Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
View source ↗ - Newsglobenewswire.com·39d ago·Neutral
MannKind to Participate in the Chardan Healthcare Conference DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), today announced that Chief Executive Officer Michael Castagna will participate in a panel focused on innovation across chronic respiratory diseases at the Chardan Healthcare Conference. Management will also participate in one-on-one meetings with investors during the conference.
View source ↗ - Newsglobenewswire.com·44d ago·Negative
MannKind Data at HFSA 2026 Highlights New Evidence Supporting Furoscix ReadyFlow™ for the Outpatient Management of Edema in Heart Failure (HF) and Chronic Kidney Disease (CKD) New analyses on Furoscix ReadyFlow PK/PD performance delivered via an autoinjector demonstrated comparable urine output to IV furosemide Consistent bioavailability, diuresis and natriuresis across injection sites support flexible administration in clinical practice Cross-study analysis demonstrates comparable diuretic and
View source ↗ - Newsmarketbeat.com·66d ago·Positive
MannKind Sees Early ReadyFlow Demand as Pediatric Afrezza Launch Gains Momentum MannKind NASDAQ: MNKD CFO Chris Prentiss outlined the company's commercial and development priorities at the H.C. Wainwright Global Investment Conference, emphasizing execution following three major 2026 catalysts: expanded pediatric approval for Afrezza, the launch of FUROSCIX ReadyFlow, and Phase 1b data for MNKD-201 in idiopathic pulmonary fibrosis, or IPF.
View source ↗ - Newsglobenewswire.com·74d ago·Negative
MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management Collaboration combines Rose Pharma investigational rapid-acting GLP-1 receptor agonist with MannKind's Technosphere ® inhalation technology MannKind to receive an equity interest and potential royalties while providing pharmaceutical development and manufacturing support through completion of a Phase 1b clinical study DANBURY, Conn. and WESTLAKE
View source ↗ - Newsglobenewswire.com·81d ago·Neutral
MannKind to Present at Upcoming Investor Conferences DANBURY, Conn. and WESTLAKE VILLAGE, Calif.
View source ↗ - Newszacks.com·86d ago·Neutral
FDA Accepts United Therapeutics' NDA Filing for Ralinepag in PAH UTHR's ralinepag NDA receives FDA acceptance, with a 2027 decision ahead as positive phase III data support its PAH potential.
View source ↗ - Newsseekingalpha.com·101d ago·Neutral
MannKind: New Approvals Majorly Increase MannKind's Prospects Three revenue streams continue to feed modest growth for MannKind. Two new FDA approvals show promise of turbocharging product growth in two of MNKD's established products. MNKD's existing liquidity should be adequate to fund its operations and launches for ~2.3 years.
View source ↗
Earnings
Thu, Feb 25(in 3 months)
Consensus estimate $0.01 per share
Typical surprise -30.7% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Nov 5$-0.01 vs $-0.07beat
- Wed, Aug 5$-0.06 vs $-0.01miss
- Wed, May 6$-0.05 vs $-0.02miss
- Thu, Feb 26$-0.05 vs $-0.01miss
- Wed, Nov 5$0.03 vs $0.01beat
- Wed, Aug 6$0.00 vs $0.04miss
Estimates and results for MNKD via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by MNKD officers and directors.
- Bought
- $259k
- Sold
- $1.6m
1 trade
10 trades
- Binder Steven B.sold
- Binder Steven B.sold
- Binder Steven B.sold
- Thomson Davidsold
- Binder Steven B.sold
- Binder Steven B.sold
- Thomson Davidsold
- Castagna Michaelbought
89 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in MNKD.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
